Corenblum B
Fertil Steril. 1979 Aug;32(2):183-6. doi: 10.1016/s0015-0282(16)44177-4.
The natural history of prolactin-secreting adenomas is not known. For this reason, optimal therapy for women harboring these adenomas who desire to conceive is also unknown. Argument can be found to favor surgical excision, radiation therapy, prolactin-suppressing chemotherapy, and clinical observation. In a large series of women with prolactin-secreting pituitary adenomas, 21 have conceived and delivered healthy infants, all of whom had ergocryptine-induced prolactin suppression as the sole form of therapy. Endocrinologic, neurologic, biochemical, and radiologic assessment failed to demonstrate any obvious growth of the pituitary adenoma, except for slight enlargement of the sella turcica in one patient who delivered twins. The failure to demonstrate any worsening of the clinical state may reflect the fact that no large tumors were included in this series, only small but definite microadenomas found on sellar tomography. All of the various modalities of therapy must be considered with each patient, but this series suggests that ergocryptine treatment with careful clinical follow-up is relatively safe in patients with small pituitary tumors.
催乳素分泌性腺瘤的自然病史尚不清楚。因此,对于患有这些腺瘤且希望怀孕的女性而言,最佳治疗方法也尚不明确。支持手术切除、放射治疗、催乳素抑制化疗以及临床观察的观点均有。在一大组患有催乳素分泌性垂体腺瘤的女性中,有21人怀孕并产下健康婴儿,她们均仅接受了麦角隐亭诱导的催乳素抑制治疗。内分泌、神经、生化及放射学评估均未显示垂体腺瘤有任何明显生长,仅1例产下双胞胎的患者蝶鞍有轻微扩大。未显示临床状态有任何恶化,这可能反映出该系列中未纳入大肿瘤,仅在蝶鞍断层扫描中发现了小而明确的微腺瘤。对于每位患者都必须考虑所有不同的治疗方式,但该系列表明,对于小垂体瘤患者,麦角隐亭治疗并进行仔细的临床随访相对安全。